Annexon, Inc. (NASDAQ:ANNX) on Tuesday presented data for its late-stage targeted therapy, tanruprubart (formerly ANX005), for Guillain-Barré Syndrome (GBS). GBS is a neuromuscular emergency affecting ...
SHREVEPORT, La. - In 2011, Shane Sumlin's life changed overnight after being diagnosed with a rare neurological disorder called Guillain-Barre syndrome (GBS). It causes the body to attack its own ...
As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another effort to improve treatment of the rare condition. Alongside a clinical data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results